Owing to the ever-increasing number of start-ups that areinvolved in R&D of novel biologics, there is an enormous opportunity forthe CMOs in this domain. It is worth emphasizing that, since 2000, more than115 new CMOs have been established in order to serve to the growing demand fornovel biologics that have specific manufacturing requirements. The contemporarycontract services market features a mix of large and small-sized CMOs and ischaracterized by multiple mergers and acquisitions as stakeholders strive tobroaden their respective service portfolios. This has enabled several CMOs tooffer end-to-end services, ranging from drug development, including preliminaryR&D, preclinical and clinical trials, to commercial scale production andregulatory filings
To order this 750+ page report, which features 200+ figuresand 250+ tables, please visit this link
The USD 13.9 billion(by 2030) financial opportunity within the biopharmaceutical manufacturing markethas been analyzed across the following segments:
§ Commonly Outsourced Business Operations
§ Active Pharmaceutical Ingredients (API)
§ Finished Dosage Formulations (FDF)
§ Types of Expression System
§ Mammalian
§ Microbial
§ Others
§ Company Size
§ Small
§ Mid-Sized
§ Large and Very Large
§ Scale of Operation
§ Preclinical
§ Clinical
§ Commercial
§ Key Geographical Region
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the World
The BiopharmaContract Manufacturing Market (3rd Edition), 2019-2030. report features thefollowing companies, which we identified to be key players in this domain:
§ 3P Biopharmaceuticals
§ Abzena
§ Albany Molecular Research
§ BioVectra
§ BioXcellence (Boehringer Ingelheim)
§ Celonic
§ Charles River Laboratories
§ ChemPartner
§ Cobra Biologics
§ CordenPharma
§ Cytovance Biologics
§ GE Healthcare
§ Goodwin Biotechnology
§ Grand River Aseptic Manufacturing
§ IDT Biologika
§ KBI BioPharma
§ Kemwell Biopharma
§ LFB Biomanufacturing
§ Meridian Life Science
§ Patheon
§ Pfizer CentreOne
§ PX'Therapeutics
§ Samsung BioLogics
§ Sanofi, CEPiA
§ Thermo Fisher Scientific
§ Vetter Pharma International
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Competitive Landscape
5. Biopharmaceutical Contract Manufacturing in NorthAmerica
6. Biopharmaceutical Contract Manufacturing in Europe
7. Biopharmaceutical Contract Manufacturing in Asia PacificAnd the Rest of The World
8. Biopharmaceutical Contract Manufacturing in Asia PacificAnd the Rest of The World
9. Case Study: Outsourcing of Biosimilars
10. Case Study: Comparison of Small Molecule and Large Molecule Drugs / Therapies
11. Case Study on In-House Manufacturing
12. Collaborations
13. Recent Developments
14. Capacity Analysis
15. Demand Analysis
16. Market Forecast
17. SWOT Analysis
18. Future of TheBiopharmaceutical CMO Market
19. Survey Analysis
20. Interview Transcripts
21. Appendix 1: List of Non-Industry Players
22. Appendix 1: List of Non-Industry Players
23. Appendix 3: List of Companies and Organizations
To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
